Proactive veideo takeaways
Post# of 151796

2) Probable license agreements with China, Taiwan and perhaps South Korea.
3) Might start treatment there before here in USA.
4) Non diluting funding: will read the non-binding terms sheets for $45m, $75M.
5) BLA submission: There is no trouble. "There are steps we have to take and will explain clearly to shareholders."
6) Perhaps some patients talk in the call of otherwise will read the testimony of them
7) "We are going directly to FDA and will filing a protocol and let FDA know what we have and going to start injecting ourselves" . Will Take a role of going forward ourselves instead of waiting for other to pay attention.

Last but not least:
Quote:
Let them decide if we are the biggest thing in Wall Street of 2020 or not.

